For instance, favorable results with vemurafenib in BRAF mutated melanoma vs limited effect in colon cancer (Flaherty et al. 2010, Kopetz et al. 2015), or panitumumab (EGFR inhibitor) in RAS WT colon cancer vs Hürthle cell cancer of the thyroid (Aydemirli et al. 2019, Battaglin et al. 2019). This evidence concerns the gene BRAF and malignant colon neoplasm.